Initial data from the phase I CHRYSALIS study evaluating amivantamab in patients with METex14 skipping mutations showed anti-tumour activity in treatment-naïve and previously-treated patients, including patients previously treated with MET inhibitors [137]. Here, MET is linked to neoplasm.